Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Diphenyleneiodonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 16/20 | 1.00 |
| ▸ | CYBB | P04839 | 2/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.93 |
| ▸ | NPC1 | O15118 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | THPO | P40225 | 1/20 | 0.93 |
| ▸ | STAT6 | P42226 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenyleneiodonium SCHEMBL159318 | 1.00 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL5547280 | 0.97 | GPR3 (0.94) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL29486373 | 0.97 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL219548 | 0.97 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL10834144 | 0.93 | GPR3 (0.93) | GPR3CYBBNOX5NOX4NOX1 | |
| Hydrochloric Acid SCHEMBL8168843 | 0.82 | — | — | |
| Diphenyleneiodonium SCHEMBL2057393 | 0.81 | GPR3 (0.73) | GPR3CYBBNOX5NOX4NOX1 | |
| SCHEMBL8367212 | 0.78 | — | — | |
| Diphenyleneiodonium SCHEMBL3733575 | 0.77 | GPR3 (0.68) | GPR3CYBBNOX5NOX4NOX1 | |
| SCHEMBL795440 | 0.70 | GPR3 (0.54) | GPR3CYBBNOX5NOX4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026046899-A1 | PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-03-05 | — | — | WO | disclosed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4514992-A2 | SYSTEM AND METHODS TO MEASURE CELL VIABILITY IN HIGH THROUGHPUT VIA CONTINUOUS GEOMETRY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| EP-3860616-B1 | AZITHROMYCIN AND ROXITHROMYCIN DERIVATIVES AS SENOLYTIC DRUGS | LUNELLA BIOTECH INC (CA) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023211926-A2 | SYSTEM AND METHODS TO MEASURE CELL VIABILITY IN HIGH THROUGHPUT VIA CONTINUOUS GEOMETRY | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11566100-B2 | Polycycloolefin polymer and inorganic nanoparticle compositions as optical materials | PROMERUS, LLC (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | NOX4, NOX1, NOX5 | GPR3 2851/4885CYBB 6/4885NOX5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.